Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints

Clinical trial NCT06616571 · RECRUITING

Trial details

NCT number: NCT06616571
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Chemotherapy-Induced Febrile Neutropenia

Start date: 2024-09-19
Primary completion: 2025-12-30
Enrollment: 336

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.